Key Data From the 2017 ICML in Lugano, Switzerland - prIME Oncology
prIME Clinical Update
prIME Clinical Update

Key Data From the 2017 ICML in Lugano, Switzerland

Critical Analysis and Practical Application

Not a member of My prIME? Join now for instant access.

Get the latest updates on malignant lymphoma from Lugano. In this CME-certified activity you can learn about newly presented data and get expert viewpoints on how trial data may impact clinical practice.

Interactive Presentation

Interactive Presentation



0.5 AMA PRA Category 1 Credit

Release Date

Release Date

Jun 20, 2017

Expiration Date

Jun 20, 2018

Abstract #37: A phase II LYSA study of obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma

Abstract #57: Clinical outcomes and molecular characterization from a phase II study of copanlisib in patients with relapsed or refractory DLBCL

Abstract #107: Immunochemotherapy with obinutuzumab or rituximab in previously untreated follicular lymphoma in the randomised phase III GALLIUM study: Analysis by chemotherapy regimen

Abstract #108: Copanlisib in patients with relapsed or refractory indolent B-cell lymphoma (CHRONOS-1)

Abstract #109: High response rates with pembrolizumab in combination with rituximab in patients with relapsed follicular lymphoma: Interim results of an on open-label, phase II study

  • Martin Dreyling, MD, PhDUniversity of Munich
    Munich, Germany
  • Georg Lenz, MD, PhDUniversity Hospital Münster
    Münster, Germany

This educational activity is designed to meet the needs of practicing hematologists, oncologists, oncology nurses, researchers, and other health care professionals involved and/or interested in the management of patients with hematologic malignancies and the consequences of these diseases.

After successful completion of this educational activity, participants should be able to:

  • Evaluate best practices regarding the treatment of patients with malignant lymphoma, including integration of novel therapeutic approaches and individualization of care

This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Key Data From the 2017 ICML in Lugano, Switzerland - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online post test and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

A link to the posttest is available on the video player page.

In order to claim credit for this activity, a score of 100% is required.

Disclosure of Relevant Financial Relationships

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Dreyling has disclosed that he received consulting fees from Bayer, Celgene, Gilead, Janssen, Mundipharma, Sandoz, and Roche. He also received speaker honoraria from Bayer, Celgene, Janssen, Gilead, and Roche. Furthermore, he has received institutional grants from Celgene, Janssen, Mundipharma, and Roche.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Lenz has disclosed that he received consulting fees from Bayer, Celgene, and Roche. He also performed contracted research for Bayer and Celgene. Furthermore, he has received fees for non-CME services from Bayer and Celgene.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Janice Galleshaw, MD (medical content reviewer) – no relevant financial relationships
  • Sanneke Koekkoek, RN (clinical content reviewer/planner) – no relevant financial relationships
  • Heather Tomlinson, ELS (editorial content reviewer) – no relevant financial relationships


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.